AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11078536 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 10
Study 11078536 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps tendon (QT) tendinous end in femoral bone tunnel
Number of subjects: 10
Study 11078536 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoButton fixation
Number of subjects: 10
Study 11078536 — intervention group
Group type: EXPERIMENTAL
Intervention: More than 20 loading cycles
Number of subjects: 10
Study 8930736 — intervention group
Group type: COMPARATOR
Intervention: Power control of energy output model
Number of subjects: 40
Study 8930736 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop temperature control model with a target electrode temperature of 70 degrees C
Number of subjects: 40
Study 1343608 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapy
Number of subjects: 0
Study 3887349 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified porcine insulins (Actrapid and Monotard)
Number of subjects: 24
Study 3887349 — intervention group
Group type: COMPARATOR
Intervention: Purified bovine insulins (Neusulin and Neuphane)
Number of subjects: 24
Study 3887349 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (bovine and porcine)
Number of subjects: 24
Study 31853960 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab (anti-IL-13 monoclonal antibody)
Number of subjects: 0
Study 31853960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29703414 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactotripeptide (LTP) ingestion for 8 weeks
Number of subjects: 15
Study 29703414 — intervention group
Group type: COMPARATOR
Intervention: Placebo ingestion for 8 weeks
Number of subjects: 15
Study 27396428 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD)
Number of subjects: 28
Study 27396428 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD) + platelet-rich fibrin (PRF)
Number of subjects: 28
Study 27396428 — intervention group
Group type: COMPARATOR
Intervention: Control (EMD)
Number of subjects: 28
Study 27396428 — intervention group
Group type: COMPARATOR
Intervention: Control (EMD + PRF)
Number of subjects: 28
Study 24066715 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol/hydrochlorothiazide (R)
Number of subjects: 156
Study 24066715 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine/valsartan (E)
Number of subjects: 156
Study 22311411 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) applied at acupoints Baihui (GV20), Sishencong (EX-HN1), Hegu (LI4), Neiguan (PC6), Taichong (LR3), Sanyinjiao (SP6), once every other day for 40 days.
Number of subjects: 112
Study 22311411 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-intervention (PI) with cognition-behavior mode implemented every 4 days for 40 days.
Number of subjects: 112
Study 22311411 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive therapy (CT) combining EA and PI for 40 days.
Number of subjects: 112
Study 20120620 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sleep deprivation
Number of subjects: 23
Study 20120620 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 23
Study 18694544 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol pMDI 640/18 microg b.i.d.
Number of subjects: 708
Study 18694544 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol pMDI 320/9 microg b.i.d.
Number of subjects: 708
Study 18694544 — intervention group
Group type: COMPARATOR
Intervention: budesonide pMDI 640 microg b.i.d.
Number of subjects: 708
Study 18694544 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol pMDI 640/18 and 320/9 microg b.i.d.
Number of subjects: 708
Study 18694544 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol 640/18 and 320/9 microg b.i.d.
Number of subjects: 708
Study 16213282 — intervention group
Group type: EXPERIMENTAL
Intervention: Equoral (IVAX, USA)
Number of subjects: 70
Study 16213282 — intervention group
Group type: COMPARATOR
Intervention: Neoral (Novartis, USA)
Number of subjects: 70
Study 16213282 — intervention group
Group type: EXPERIMENTAL
Intervention: Equoral and Neoral
Number of subjects: 70
Study 11388028 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention, specific details not provided
Number of subjects: 0
Study 11388028 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoprevention through nutritional modification, specific details not provided
Number of subjects: 0
Study 9272472 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic management (spinal manipulation, soft tissue therapy, passive stretching for 4 weeks)
Number of subjects: 21
Study 9272472 — intervention group
Group type: COMPARATOR
Intervention: Chiropractic management withheld for 4 weeks (control group)
Number of subjects: 21
Study 7944920 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS at 99Hz over the common peroneal nerve (CPN) for 30 minutes
Number of subjects: 11
Study 7944920 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS at 99Hz over the sural nerve for 30 minutes
Number of subjects: 11
Study 7944920 — intervention group
Group type: COMPARATOR
Intervention: TENS at 50Hz over the CPN or sural nerve
Number of subjects: 11
Study 7944920 — intervention group
Group type: COMPARATOR
Intervention: Control values (Hctrl) measured for 5 minutes prior and 10 minutes after TENS
Number of subjects: 11
Study 3205676 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide
Number of subjects: 12
Study 3205676 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (tablets)
Number of subjects: 12
Study 1972334 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone 0.5 mg kg‐1 as a bolus (n = 10)
Number of subjects: 20
Study 1972334 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine 5 micrograms kg‐1 min‐1
Number of subjects: 20
Study 902653 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 X 6 min workloads (3 min rest between each bout)
Number of subjects: 9
Study 902653 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 X 4 min workloads (1 1/2 min rest between each bout)
Number of subjects: 9
Study 902653 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 X 3 min workloads (1 min rest between each bout)
Number of subjects: 9
Study 902653 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with VO2 max
Number of subjects: 9
Study 902653 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted VO2 max from Astrand-Ryhming nomogram
Number of subjects: 9
Study 31792670 — intervention group
Group type: EXPERIMENTAL
Intervention: TELEmedicine intervention for IBD patients
Number of subjects: 0
Study 31792670 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 31189287 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate and benzydamine hydrochloride solution
Number of subjects: 83
Study 31189287 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and phosphate solution
Number of subjects: 83
Study 31189287 — intervention group
Group type: EXPERIMENTAL
Intervention: Black mulberry syrup
Number of subjects: 83
Study 27642057 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA meal
Number of subjects: 54
Study 27642057 — intervention group
Group type: EXPERIMENTAL
Intervention: CARB meal
Number of subjects: 54
Study 27642057 — intervention group
Group type: COMPARATOR
Intervention: CARB diet
Number of subjects: 54
Study 27642057 — intervention group
Group type: COMPARATOR
Intervention: SFA diet
Number of subjects: 54
Study 26206173 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-perceived food addicts
Number of subjects: 210
Study 23419226 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram for 13 weeks
Number of subjects: 67
Study 23419226 — intervention group
Group type: EXPERIMENTAL
Intervention: ATR+ status
Number of subjects: 67
Study 23419226 — intervention group
Group type: EXPERIMENTAL
Intervention: ATR- status
Number of subjects: 67
Study 23419226 — intervention group
Group type: EXPERIMENTAL
Intervention: ATR+ subjects
Number of subjects: 67
Study 23419226 — intervention group
Group type: EXPERIMENTAL
Intervention: ATR- individuals
Number of subjects: 67
Study 20195844 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity (80% 1RM), 2 days/week (2HI)
Number of subjects: 124
Study 20195844 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity (40% 1RM), 2 days/week (2LI)
Number of subjects: 124
Study 20195844 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity (80% 1RM), 3 days/week (3HI)
Number of subjects: 124
Study 20195844 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity (40% 1RM), 3 days/week (3LI)
Number of subjects: 124
Study 20195844 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 124
Study 20195844 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 124
Study 19439506 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with thyroid hormone (TH) including thyroxine and T(3) in prolonged critically ill rabbits
Number of subjects: 0
Study 19439506 — intervention group
Group type: COMPARATOR
Intervention: Prolonged critically ill patients
Number of subjects: 0
Study 19439506 — intervention group
Group type: COMPARATOR
Intervention: Rabbit model of prolonged critical illness
Number of subjects: 0
Study 17574679 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial progenitor cells (EPCs) therapy
Number of subjects: 0
Study 17574679 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 16328638 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of oral celecoxib administered 30 min before surgery
Number of subjects: 695
Study 16328638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 695
Study 11176439 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser tissue soldering
Number of subjects: 138
Study 11176439 — intervention group
Group type: COMPARATOR
Intervention: Conventional suturing
Number of subjects: 138
Study 9399015 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 2.5 mg
Number of subjects: 2480
Study 9399015 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 5 mg
Number of subjects: 2480
Study 9399015 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan
Number of subjects: 2480
Study 7950168 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO 150 U/kg s.c. once daily for two consecutive days
Number of subjects: 95
Study 7950168 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO 150 U/kg i.v. once daily for two consecutive days
Number of subjects: 95
Study 7950168 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO 300 U/kg s.c. once only
Number of subjects: 95
Study 7950168 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO 300 U/kg i.v. once only
Number of subjects: 95
Study 7950168 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (not specified)
Number of subjects: 95
Study 7950168 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO 300 U/kg body weight (single-shot)
Number of subjects: 95
Study 2823313 — intervention group
Group type: EXPERIMENTAL
Intervention: LTB4
Number of subjects: 10
Study 2823313 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2
Number of subjects: 10
Study 2823313 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of LTB4 and PGE2
Number of subjects: 10
Study 29029857 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 46
Study 28448398 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 μg/kg EREM
Number of subjects: 71
Study 28448398 — intervention group
Group type: COMPARATOR
Intervention: 7.5 μg/kg IT morphine
Number of subjects: 71
Study 25643790 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEPO-b (100,000 iu)
Number of subjects: 40
Study 25643790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23758655 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary surgery followed by adjuvant chemotherapy (6 cycles of Epirubicin, cisplatin, 5-fluorouracil)
Number of subjects: 314
Study 23758655 — intervention group
Group type: COMPARATOR
Intervention: Perioperative chemotherapy (2x3 cycles of Epirubicin, cisplatin, 5-fluorouracil)
Number of subjects: 314
Study 21963186 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant treatment during spontaneous breathing via a thin catheter
Number of subjects: 220
Study 21963186 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 220
Study 18342224 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronicle (Medtronic Inc., Minneapolis, Minnesota)
Number of subjects: 274
Study 18342224 — intervention group
Group type: COMPARATOR
Intervention: Control group (optimal medical therapy without hemodynamic monitoring)
Number of subjects: 274
Study 17161769 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive BP control with valsartan (diastolic BP goal 75 mm Hg)
Number of subjects: 129
Study 17161769 — intervention group
Group type: COMPARATOR
Intervention: Moderate BP control (diastolic BP 80 to 90 mm Hg with placebo)
Number of subjects: 129
Study 14563182 — intervention group
Group type: EXPERIMENTAL
Intervention: 13C‐urea‐breath test (UBT)
Number of subjects: 314
Study 14563182 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme Immunoassay (EIA)
Number of subjects: 314
Study 14563182 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Urease Test (RUT)
Number of subjects: 314
Study 14563182 — intervention group
Group type: EXPERIMENTAL
Intervention: Histology
Number of subjects: 314
Study 14563182 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture
Number of subjects: 314
Study 14563182 — intervention group
Group type: EXPERIMENTAL
Intervention: 13C‐urea‐breath test (UBT) in elderly patients (>65 years old, n=120)
Number of subjects: 314
Study 11303053 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib in solution
Number of subjects: 0
Study 11303053 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib in capsule
Number of subjects: 0
Study 11303053 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib intragastrically in solution
Number of subjects: 0
Study 11303053 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib in humans with high fat meal
Number of subjects: 0
Study 11303053 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib in humans
Number of subjects: 0
Study 9076853 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation group (progressive muscle relaxation and modified autogenic training)
Number of subjects: 3
Study 9076853 — intervention group
Group type: COMPARATOR
Intervention: Ordinary supportive psychotherapy group
Number of subjects: 3
Study 9076853 — intervention group
Group type: COMPARATOR
Intervention: No psychiatric treatment group
Number of subjects: 3
Study 8195440 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% chlorhexidine
Number of subjects: 28
Study 8195440 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% chlorhexidine
Number of subjects: 28
Study 8195440 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% chlorhexidine
Number of subjects: 28
Study 8195440 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine
Number of subjects: 28
Study 8195440 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% triclosan
Number of subjects: 28
Study 8195440 — intervention group
Group type: COMPARATOR
Intervention: minus active control for chlorhexidine
Number of subjects: 28
Study 8195440 — intervention group
Group type: COMPARATOR
Intervention: minus active control for triclosan
Number of subjects: 28
Study 3370132 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulant during the day (group A; n = 19)
Number of subjects: 38
Study 3370132 — intervention group
Group type: COMPARATOR
Intervention: Bed rest (group B; n = 19)
Number of subjects: 38
Study 3370132 — intervention group
Group type: COMPARATOR
Intervention: Sensory deprivation during the first 4 hours of blood pressure recording (group B)
Number of subjects: 38
Study 3370132 — intervention group
Group type: COMPARATOR
Intervention: Bed rest alone (group B)
Number of subjects: 38
Study 3370132 — intervention group
Group type: COMPARATOR
Intervention: Night rest (group B)
Number of subjects: 38
Study 3370132 — intervention group
Group type: COMPARATOR
Intervention: Sensory deprivation (group B)
Number of subjects: 38
Study 3370132 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulant (group A)
Number of subjects: 38
Study 31847574 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise plus stretching (once per week for 12 weeks)
Number of subjects: 64
Study 31847574 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity aerobic exercise (control group)
Number of subjects: 64
Study 30607000 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic machine perfusion (NMP)
Number of subjects: 24
Study 30607000 — intervention group
Group type: COMPARATOR
Intervention: Cold preservation (CS)
Number of subjects: 24
Study 27599913 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg
Number of subjects: 304
Study 27599913 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilastine 10 mg
Number of subjects: 304
Study 27599913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study 25347968 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 75.4 g kg(‐1) lipid level
Number of subjects: 120
Study 25347968 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 51.4 g kg(‐1) lipid level
Number of subjects: 120
Study 25347968 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with lipid levels (general finding)
Number of subjects: 120
Study 25347968 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with increasing lipid levels
Number of subjects: 120
Study 25347968 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with lipid levels
Number of subjects: 120
Study 25347968 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-fed groups
Number of subjects: 120
Study 23541174 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-student model
Number of subjects: 16
Study 23541174 — intervention group
Group type: COMPARATOR
Intervention: One-student model
Number of subjects: 16
Study 23541174 — intervention group
Group type: EXPERIMENTAL
Intervention: Both models
Number of subjects: 16
Study 21506352 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern physical techniques (electrosurgical, radiosurgical, argon-plasma dissector)
Number of subjects: 272
Study 19027013 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine
Number of subjects: 1367
Study 16960700 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg
Number of subjects: 60
Study 16960700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15574087 — intervention group
Group type: EXPERIMENTAL
Intervention: Wingate test (30 seconds)
Number of subjects: 20
Study 15574087 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosco test (60 seconds)
Number of subjects: 20
Study 15574087 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tests
Number of subjects: 20
Study 15574087 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosco test
Number of subjects: 20
Study 10917072 — intervention group
Group type: EXPERIMENTAL
Intervention: Class II agents (beta-blockers)
Number of subjects: 0
Study 10917072 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0
Study 10917072 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0
Study 10917072 — intervention group
Group type: COMPARATOR
Intervention: Class I antiarrhythmic agents
Number of subjects: 0
Study 10917072 — intervention group
Group type: EXPERIMENTAL
Intervention: d,l-sotalol
Number of subjects: 0
Study 10917072 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexsotalol
Number of subjects: 0
Study 10917072 — intervention group
Group type: COMPARATOR
Intervention: Calcium antagonists (class IV agents)
Number of subjects: 0
Study 10917072 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable defibrillators
Number of subjects: 0
Study 8807684 — intervention group
Group type: EXPERIMENTAL
Intervention: Day hospital-crisis respite program
Number of subjects: 0
Study 8807684 — intervention group
Group type: COMPARATOR
Intervention: Inpatient setting
Number of subjects: 0
Study 1570084 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (500 IU/day)
Number of subjects: 100
Study 1570084 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 IU/day)
Number of subjects: 100
Study 3931107 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ritanserin
Number of subjects: 83
Study 3931107 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg lorazepam
Number of subjects: 83
Study 3931107 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg ritanserin
Number of subjects: 83
Study 3931107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 31060275 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip-Hop to Health (HH)
Number of subjects: 153
Study 31060275 — intervention group
Group type: COMPARATOR
Intervention: Standard Nutrition Education (NE)
Number of subjects: 153
Study 28511594 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 distal screws of a volar plate
Number of subjects: 10
Study 28511594 — intervention group
Group type: COMPARATOR
Intervention: 4 distal screws of a volar plate
Number of subjects: 10
Study 27543563 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patches (5-week supply)
Number of subjects: 1000
Study 27543563 — intervention group
Group type: COMPARATOR
Intervention: No intervention control
Number of subjects: 1000
Study 24271650 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV-biofeedback
Number of subjects: 48
Study 24271650 — intervention group
Group type: COMPARATOR
Intervention: Control sessions
Number of subjects: 48
Study 22225544 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic-enriched artichokes (180 g per day, 2 × 10(10) CFU of Lactobacillus paracasei IMPC 2.1)
Number of subjects: 20
Study 22225544 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic-enriched artichokes
Number of subjects: 20
Study 20128566 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg intravitreal dexamethasone
Number of subjects: 12
Study 20128566 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg intravitreal dexamethasone
Number of subjects: 12